Sandoz Eyes First-To-Market US Opportunities With Adalvo Deal

Targeting Six Antifungal/Antibiotic, Oncology And Pulmonary Drugs Worth $3bn

Sandoz has struck a deal with Adalvo that will give the company rights to six products in the US – four of which are potential first-to-market opportunities – targeting markets that are collectively worth around $3bn.

Dice showing all sixes
Sandoz has struck a deal with Adalvo for six products • Source: Shutterstock

Sandoz and Adalvo have struck a distribution and collaboration deal that will give Sandoz exclusive rights to sell six undisclosed products in the US market, covering what Sandoz described as the “key areas” of anti-infectives and oncology.

While specific launch dates for the products were not identified, the firms said that the “near- to mid-term launches” would...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business